Cyclerion Therapeutics, Inc.
16 more in force are now held by other companies
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.
0
Ending by 2030
Jun 2031
Next term end
When these terms end
Held patents by the year their term ends
20262027202820292030203120322033203420352036203720382039204020412042204320442045
Fee deadlines
Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
- 1 fee due Dec 23, 2026The maintenance fee for sGC stimulators (US 9,061,030) comes due Dec 23, 2026. Unpaid by Jun 23, 2027, it lapses early.
- 1 fee due Jan 25, 2027The maintenance fee for Novel Processes and Intermediates for the Preparation of Soluble Guanylate Cyclase Stimulators (US 11,708,361) comes due Jan 25, 2027. Unpaid by Jul 26, 2027, it lapses early.
- 1 fee due Mar 22, 2027The maintenance fee for 2-benzyl, 3-(pyrimidin-2-yl) substituted pyrazoles useful as sGC stimulators (US 9,139,564) comes due Mar 22, 2027. Unpaid by Sep 22, 2027, it lapses early.
- 1 fee due Apr 3, 2027The maintenance fee for Process for Preparation of Soluble Guanylate Cyclase Stimulators (US 11,773,089) comes due Apr 3, 2027. Unpaid by Oct 4, 2027, it lapses early.
- 1 fee due Jun 30, 2027The maintenance fee for sGC STIMULATORS (US 10,517,874) comes due Jun 30, 2027. Unpaid by Jan 3, 2028, it lapses early.
- 1 fee due Nov 5, 2027The maintenance fee for sGC STIMULATORS (US 10,639,308) comes due Nov 5, 2027. Unpaid by May 5, 2028, it lapses early.
Recent changes
- 1 of the patents on this record was granted since Aug 18, 2026
Patents held now
Soonest term end first. Each date below is computed on that patent's own page, which shows the rule, the adjustments and the fee history it was derived from.
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 10,189,809 | sGC STIMULATORS In force · High confidence | In force | High confidence | |
| US 8,748,442 | SGC Stimulators In force · High confidence | In force | High confidence | |
| US 9,061,030 | sGC stimulators In force · From the USPTO record | In force | From the USPTO record | |
| US 9,139,564 | 2-benzyl, 3-(pyrimidin-2-yl) substituted pyrazoles useful as sGC stimulators In force · From the USPTO record | In force | From the USPTO record | |
| US 9,481,689 | sGC STIMULATORS In force · High confidence | In force | High confidence | |
| US 9,586,937 | sGC STIMULATORS In force · High confidence | In force | High confidence | |
| US 10,183,021 | sGC STIMULATORS In force · High confidence | In force | High confidence | |
| US 10,517,874 | sGC STIMULATORS In force · High confidence | In force | High confidence | |
| US 10,639,308 | sGC STIMULATORS In force · High confidence | In force | High confidence | |
| US 11,207,323 | sGC STIMULATORS In force · Medium confidence | In force | Medium confidence |
Also on record, not counted in the 20: 16 patents in force now held by others · 4 lapsed for an unpaid fee. List them
Sources and methods
Compiled from the USPTO record, grants, published applications and recorded assignments, not yet reviewed by hand.
How this record was built
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.
Published applications
US patent applications published under this name that have not become patents. An application is published about eighteen months after its earliest filing; one that has not been published is in no public record.
5 pending · 9 abandoned · 9 no status recorded